A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir

BackgroundNew multi-purpose prevention technology (MPT) products are needed to prevent human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV2). In this study, we evaluated a fast-dissolve insert that may be used vaginally or rectally for prevention of infection.ObjectiveTo describe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Andrea R. Thurman, Louise A. Ouattara, Nazita Yousefieh, Peter L. Anderson, Lane R. Bushman, Xi Fang, Homaira Hanif, Meredith Clark, Onkar Singh, Gustavo F. Doncel
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-04-01
coleção:	Frontiers in Cellular and Infection Microbiology
Assuntos:	vaginal insert tenofovir alafenamide elvitegravir microbicide agent HIV prevention
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fcimb.2023.1130101/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!